ArticlePediatric blood & cancer2026
Increased Risk of Sarcomas in Children With Congenital Anomalies: Findings From the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Registry Linkage Study.
Article in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPediatric sarcomas are a heterogeneous group of tumors that contribute disproportionately to cancer mortality in children. Although congenital anomalies are among the strongest known risk factors for childhood cancer, the risk of specific sarcoma subtypes among affected individuals has not yet been thoroughly evaluated. PROCEDURE: We obtained data on maternal and perinatal characteristics, congenital anomalies, and pediatric sarcoma diagnoses for all live births in nine states. We used Cox proportional hazards regression to estimate the hazard ratio (HR) and 95% confidence interval (CI) of sarcoma (overall and by subtype) among children with non-syndromic congenital anomalies. We considered all non-syndromic anomalies collectively, and when sample size allowed, we also evaluated specific anomaly-sarcoma associations.
resultsWe evaluated 21,933,884 children, including 641,770 (2.9%) with major non-syndromic congenital anomalies. Compared to children without a congenital anomaly, children with a non-syndromic anomaly had a two-fold higher hazard for any soft tissue sarcoma (95% CI: 1.7-2.5), including rhabdomyosarcoma (HR 2.2, 95% CI: 1.7-3.0) and embryonal rhabdomyosarcoma (HR 2.5, 95% CI: 1.8-3.6), as well as non-rhabdomyosarcoma soft tissue sarcoma (HR 1.8, 95% CI: 1.3-2.5). The hazard of embryonal rhabdomyosarcoma was markedly increased in children with central nervous system anomalies (HR 7.9, 95% CI: 3.9-15.9), obstructive genitourinary defects (HR 4.6, 95% CI: 2.2-9.7), and limb reduction deformities (HR 3.8, 95% CI: 1.6-9.3).
conclusionsChildren with non-syndromic congenital anomalies are at increased risk of sarcomas, especially soft tissue sarcomas. Future studies should clarify shared developmental pathways and evaluate implications for sarcoma risk prediction and surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.